Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone
- PMID: 9745404
- DOI: 10.1210/jcem.83.9.5120
Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone
Abstract
Prolonged critical illness is characterized by feeding-resistant wasting of protein, whereas reesterification, instead of oxidation of fatty acids, allows fat stores to accrue and associate with a low-activity status of the somatotropic and thyrotropic axis, which seems to be partly of hypothalamic origin. To further unravel this paradoxical metabolic condition, and in search of potential therapeutic strategies, we measured serum concentrations of leptin; studied the relationship with body mass index, insulin, cortisol, thyroid hormones, and somatomedins; and documented the effects of hypothalamic releasing factors, in particular, GH-secretagogues and TRH. Twenty adults, critically ill for several weeks and supported with normocaloric, continuously administered parenteral and/or enteral feeding, were studied for 45 h. They had been randomized to receive one of three combinations of peptide infusions, in random order: TRH (one day) and placebo (other day); TRH + GH-releasing peptide (GHRP)-2 and GHRP-2; TRH + GHRH + GHRP-2 and GHRH + GHRP-2. Peptide infusions were started after a 1-microgram/kg bolus at 0900 h and infused (1 microgram/kg.h) until 0600 h the next morning. Serum concentrations of leptin, insulin, cortisol, T4, T3, insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the acid-labile subunit (ALS) were measured at 0900 h, 2100 h, and 0600 h on each of the 2 study days. Baseline leptin levels (mean +/- SEM: 12.4 +/- 2.1 micrograms/L) were independent of body mass index (25 +/- 1 kg/m2), insulin (18.6 +/- 2.9 microIU/mL), cortisol (504 +/- 43 mmol/L), and thyroid hormones (T4: 63 +/- 5 nmol/L, T3: 0.72 +/- 0.08 nmol/L) but correlated positively with circulating levels of IGF-I [86 +/- 6 micrograms/L, determination coefficient (R2) = 0.25] and ALS (7.2 +/- 0.6 mg/L, R2 = 0.32). Infusion of placebo or TRH had no effect on leptin. In contrast, GH-secretagogues elevated leptin levels within 12 h. Infusion of GHRP-2 alone induced a maximal leptin increase of +87% after 24 h, whereas GHRH + GHRP-2 elevated leptin by up to +157% after 24 h. The increase in leptin within 12 h was related (R2 = 0.58) to the substantial rise in insulin. After 45 h, and having reached a plateau, leptin was related to the increased IGF-I (R2 = 0.37). In conclusion, circulating leptin levels during protracted critical illness were linked to the activity state of the GH/IGF-I axis. Stimulating the GH/IGF-I axis with GH-secretagogues increased leptin levels within 12 h. Because leptin may stimulate oxidation of fatty acids, and because GH, IGF-I, and insulin have a protein-sparing effect, GH-secretagogue administration may be expected to result in increased utilization of fat as preferential substrate and to restore protein content in vital tissues and, consequently, has potential as a strategy to reverse the paradoxical metabolic condition of protracted critical illness.
Similar articles
-
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.J Clin Endocrinol Metab. 1997 Feb;82(2):590-9. doi: 10.1210/jcem.82.2.3736. J Clin Endocrinol Metab. 1997. PMID: 9024260 Clinical Trial.
-
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.Clin Endocrinol (Oxf). 1996 Sep;45(3):341-51. doi: 10.1046/j.1365-2265.1996.00805.x. Clin Endocrinol (Oxf). 1996. PMID: 8949573 Clinical Trial.
-
Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.J Clin Endocrinol Metab. 1998 Feb;83(2):309-19. doi: 10.1210/jcem.83.2.4575. J Clin Endocrinol Metab. 1998. PMID: 9467533 Clinical Trial.
-
Growth hormone secretagogues in critical illness.Horm Res. 1999;51 Suppl 3:21-8. doi: 10.1159/000053158. Horm Res. 1999. PMID: 10592440 Review.
-
Endocrinology in intensive care medicine: new insights and therapeutic consequences.Verh K Acad Geneeskd Belg. 2002;64(3):167-87; discussion 187-8. Verh K Acad Geneeskd Belg. 2002. PMID: 12238241 Review.
Cited by
-
The Neurological Metabolic Phenotype in Prolonged/Chronic Critical Illness: Propensity Score Matched Analysis of Nutrition and Outcomes.Nutrients. 2025 Jul 12;17(14):2302. doi: 10.3390/nu17142302. Nutrients. 2025. PMID: 40732927 Free PMC article.
-
Definitions, epidemiology, and outcomes of persistent/chronic critical illness: a scoping review for translation to clinical practice.Crit Care. 2024 Dec 28;28(1):435. doi: 10.1186/s13054-024-05215-4. Crit Care. 2024. PMID: 39731183 Free PMC article.
-
Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article.Mol Med. 2025 Jan 21;31(1):16. doi: 10.1186/s10020-025-01074-z. Mol Med. 2025. PMID: 39838305 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous